Pemigatinib Induces Responses in Second-Line FGFR+ Cholangiocarcinoma
September 28th 2019An objective response rate of 35.5% was seen with treatment with pemigatinib, a selective oral inhibitor of FGFR1, 2, and 3, in patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an <em>FGFR2 </em>rearrangement or fusion, according to findings from the phase II FIGHT-202 clinical trial presented at ESMO 2019.
Read More
Survival Benefit Seen With Atezolizumab in High PD-L1 NSCLC
September 28th 2019Single-agent atezolizumab improved overall survival in newly diagnosed patients with wild-type non–small cell lung cancer who had ≥50% expression of PD-L1 on tumor cells or ≥10% expression on tumor-infiltrating immune cells compared with platinum-based chemotherapy, according to the interim survival analysis of the phase III IMpower110 study.
Read More
Trend in OS Benefit Seen With Apalutamide in SPARTAN Trial for Nonmetastatic CRPC
September 27th 2019In the phase III SPARTAN trial, the combination of androgen receptor apalutamide and androgen deprivation therapy led to an overall survival OS benefit compared with placebo/androgen deprivation therapy in patients with nonmetastatic castration-resistant prostate cancer, based on the updated findings presented at the 2019 ESMO Congress.
Read More
Perioperative Nivolumab/Ipilimumab Combo Showing Early Promising Results in HCC
September 24th 2019Pathologic complete responses were seen in 29% of patients with resectable hepatocellular carcinoma treated with a perioperative immunotherapy regimen in the first interim analysis of a phase II trial, reported Yehia I. Abugabal, MD, in his presentation at the 2019 ILCA Annual Conference.
Read More
Atezolizumab Plus Bevacizumab Offers a Promising Option for Unresectable HCC
September 23rd 2019Clinically meaningful and durable objective responses were observed in the phase Ib subgroup efficacy analysis of atezolizumab plus bevacizumab in patients with previously untreated, unresectable hepatocellular carcinoma.
Read More
Real-Life Analysis Confirms Benefit of Sorafenib/Regorafenib Sequence in HCC
September 23rd 2019In an interview with <em>Targeted Oncology</em>, María Varela, MD, PhD, discussed the rationale of the findings from the real-life analysis and their importance for patients with HCC being treated outside of a clinical trial.
Read More
Second-Line Pembrolizumab Confers Improved OS, PFS in Patients With Advanced HCC
September 22nd 2019The final analysis of KEYNOTE-240, a phase III study of pembrolizumab in advanced hepatocellular cancer, demonstrated favorable benefit in overall survival and progression-free survival, according to Richard S. Finn, MD, during his presentation at the 13th Annual Conference of the International Liver Cancer Association in Chicago.
Read More
Curative and Palliative Treatment Options for Patients With Hepatocellular Carcinoma
September 22nd 2019Amit Singal, MD, discusses the current treatment landscape for patients with hepatocellular carcinoma and how the treatments differ among patients caught in early-stage versus late-stage at the 2019 International Liver Cancer Association Annual Conference.
Watch
RESORCE Trial Analysis Shows Higher AFP Responses Achieved With Regorafenib in HCC
September 22nd 2019Treatment with regorafenib resulted in higher rates of alpha-fetoprotein level response compared with placebo in patients with unresectable hepatocellular carcinoma who had progressed on prior sorafenib, according to an analysis from the phase III RESORCE trial.
Read More
AFP Response Could Assist in Cabozantinib Therapy Selection in HCC
September 22nd 2019Patients with advanced hepatocellular carcinoma treated with cabozantinib had higher alpha-fetoprotein response rates versus those treated with placebo, according to findings of a subanalysis of the phase III CELESTIAL trial.
Read More
Expert Speaks to Non-Alcoholic Fatty Liver Disease-Related Mortality and Development of HCC
September 21st 2019In an interview with <em>Targeted Oncology</em>, Katherine A. McGlynn, PhD, MPH, discussed the population attributable fraction of non-alcoholic fatty liver disease in developing hepatocellular carcinoma, as well as related disorders, in the United States that contribute to the risk of mortality.<br />
Read More
Safety of Nivolumab/Ipilimumab Combination Confirmed for Advanced HCC
September 21st 2019For those with advanced hepatocellular carcinoma, the CheckMate 040 study found that the combination can be effective. Information from that study found that the combination can also yield a favorable safety profile, said Anthony B. El-Khoueiry, MD, in his presentation at the 2019 ILCA Annual Conference.
Read More
STOMP Trial Shows High Activity in R/R Multiple Myeloma With Selinexor Regimen
September 17th 2019Selinexor plus lenalidomide and dexamethasone, an all-oral triplet, was found to be highly active in patients with relapsed or refractory multiple myeloma, according to results of the multi-arm STOMP study that were presented during the 17th International Myeloma Workshop. The regimen is also well tolerated and especially active in patients who did not receive lenalidomide prior to the trial.
Read More
The combination of melflufen and dexamethasone showed antitumor activity in patients with relapsed or refractory multiple myeloma, both in those with and those without extramedullary disease, according to data from the phase II HORIZON study presented at the 17th International Myeloma Workshop.
Read More
Daratumumab Plus VRd Improved Depth of Response in Transplant-Eligible, Newly Diagnosed Myeloma
September 15th 2019The GRIFFIN study showed that the addition of daratumumab to bortezomib, lenalidomide, and dexamethasone, improved stringent complete response in transplant-eligible patients with newly diagnosed multiple myeloma without affecting stem cell mobilization or hematopoietic reconstitution, according to results presented at the 17th International Myeloma Workshop.
Read More
Antitumor Activity Observed With Iberdomide in Heavily Pretreated Myeloma
September 15th 2019Novel agent iberdomide in combination with dexamethasone was safe and demonstrated antitumor activity in patients with relapsed/refractory multiple myeloma who were heavily pretreated, according to findings from a phase Ib/IIa trial presented at the 17th International Myeloma Workshop.
Read More
Real-World Data Show Tisagenlecleucel is an Effective Treatment for DLBCL
September 15th 2019In a prospective postmarketing assessment, the use of tisagenlecleucel for treatment of adult patients with diffuse large B-cell lymphoma, lead to responses that were similar to studies of children and adolescents with B-cell acute lymphoblastic leukemia.
Read More
Promising PFS Shown With Isatuximab Triplet in High-Risk Multiple Myeloma
September 15th 2019In an interview with <em>Targeted Oncology</em> during the 17th IMW Scientific Program, Simon J. Harrison, MBBS, PhD, discussed the subgroup findings from the ICARIA-MM study in relapsed/refractory multiple myeloma.
Read More
Melflufen Plus Dexamethasone Safe and Effective For R/R Multiple Myeloma
September 15th 2019Paul G. Richardson, MD, clinical program leader and director of clinical research of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and RJ Corman Professor of Medicine, Harvard School of Medicine, discusses the interesting safety and efficacy profiles of the HORIZON trial.
Watch
More Research and Development on JAK Inhibition May Improve Myelofibrosis Management
September 15th 2019In an interview with <em>Targeted Oncology </em>during the 2019 SOHO Annual Meeting, <mark style="background-color:inherit; color:inherit; font-size:14px">Laura C. Michaelis, MD, </mark>discussed the currently approved JAK inhibitors and the future landscape for myelofibrosis, as well as treatment considerations for graft-versus-host disease.
Read More
Efficacy Seen With Isatuximab Regimen in High-Risk Multiple Myeloma
September 14th 2019The addition of isatuximab to carfilzomib, lenalidomide, and dexamethasone led to a response rate in all 10 patients included in a safety run-in cohort of the phase II, multicenter GMMG-CONCEPT trial.
Read More
Daratumumab-Based Quadruplet Demonstrates Efficacy in High-Risk Myeloma Subgroups
September 14th 2019Daratumumab in combination with bortezomib, thalidomide, and dexamethasone demonstrated benefit compared with VTd alone in subgroup analyses of patients with high-risk multiple myeloma from the phase III CASSIOPEIA trial.
Read More
Phase II JULIET Study Continues To Show Benefit of Tisagenlecleucel in DLBCL
September 14th 2019Recent updates to the JULIET study, presented at the 2019 SOHO Annual Meeting, show that tisagenlecleucel has sustained benefit throughout the course of the trial with high response rates, and long duration in adults with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Improvement in PFS Shown With Checkpoint Inhibition Before Transplantation in R/R Hodgkin Lymphoma
September 13th 2019In a retrospective study of patients with replaced or refractory Hodgkin lymphoma, checkpoint inhibition prior to haploidentical stem cell transplantation improved progression-free survival and risk for relapse, based on results presented at the 2019 SOHO Annual Meeting.
Read More
Fedratinib Approval Further Validates JAK Inhibition for Myelofibrosis Treatment
September 13th 2019In an interview with <em>Targeted Oncology </em>during the 2019 SOHO Annual Meeting, Ruben Mesa, MD, discussed the JAKARTA and JAKARTA-2 studies and the implications their data have on the field of myelofibrosis.
Read More
Pemmaraju Reviews Potential Combination Regimens With Ruxolitinib for Myelofibrosis
September 13th 2019Naveen Pemmaraju, MD, discussed potential combination regimens with ruxolitinib (Jakafi) being explored to improve outcomes for patients with myelofibrosis at the 2019 SOHO Annual Meeting.
Read More